  The present Health Crisis tests the response of modern science and medicine
to finding treatment for a new COVID-19 disease. The presentation on the world
stage of antivirals such as remdesivir, obeys to the continuous investigation
of biologically active molecules with multiple theoretical, computational and
experimental tools. Diseases such as COVID:19 remind us that research into
active ingredients for therapeutic purposes should cover all available sources,
such as plants. In the present work, in silico tools, specifically docking
study, were used to evaluate the binding and inhibition capacity of an
antiviral such as remdesivir on the NSP-12 protein of SARS-CoV, a polymerase
that is key in the replication of the SARS-COV virus. The results are then
compared with a docking analysis of two natural products (Alpha-Bisabolol and
betalain) with SARS-CoV protein, in order to find more candidates for COVID-19
virus replication inhibitors. in addition to increasing studies that help
explain the specific mechanisms of the SARs-CoV-2 virus, remembering that we
will have to live with the virus for an indefinite time from now on. Finally,
natural products such as betalains may have inhibitory effects of a small order
but in conjunction with other synergistic active ingredients they may increase
their inhibition effect on NSP-12 protein of SARS-CoV.
